


D. Fitzgerald

BIOTECHNOLOGY
SYSTEMS
BRANCH

RAW SEQUENCE LISTING **ERROR REPORT**



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 09/029,042A
Art Unit / Team No: 1646
Date Processed by STIC: 10/28/99

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,

2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

MARK SPENCER 703-308-4212

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/029,042A

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 Wrapped Aminos The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 Misaligned Amino Acid Numbering The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.
- 7 PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.
- 8 Skipped Sequences (OLD RULES) Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 Skipped Sequences (NEW RULES) Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 10 Use of n's or Xaa's (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 Use of <213>Organism (NEW RULES) Sequence(s) are missing this mandatory field or its response.
- 12 Use of <220>Feature (NEW RULES) Sequence(s) are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

PAGE: 1

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042ADATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

This Raw Listing contains the General
Information Section and those Sequences
containing ERRORS.Does Not Comply
Corrected Diskette Needed

- 1 <110> Kim, Sun-Young; Kim, Kee-Won; Kim, Tae-Han; Hwang, Jeong-Ho; Kim, Seon-Hee; L
2 <120> Heterologous Protein Production System using Avian Cells
3 <130>
4 <140> US/09/029,042A
5 <141> 1998-05-15
6 <150> PCT/KR96/00145
7 <151> 1996-08-23
8 <160> 11

W--> OK

Please consult
new sequence Rules
and sample sequence
listing (attached in back)
for valid format.

all text
must be
visible -
see item 3
on Error
summary sheet

ERRORED SEQUENCES FOLLOW

insert sequence number NEXT TO <400>

9 <210> 1
10 <211> 1584
11 <212> DNA
12 <213> erythropoietin
13 <400> ATGGGGGTGC ACGAATGTCC TGCCTGGCTG TGGCTTCTCC TGTCCTGTCT
14 GTCGCTCCCT CTGGGCCTCC CAGTCTGGG CGCCCCACCA CGCCTCATCT
15
16 GTGACAGCCG AGTCTGGAG AGGTACCTCT TGGAGGCCAA GGAGGCCGAG
17
18 AATATCACGG TGAGACCCCT TCCCCAGCAC ATTCCACAGA ACTCACGCTC
19
20 AGGGCTTCAG GG-AACTCCT CCCAG-ATCC AGGAACCTGG CACTTGGTTT
21
22 GGGGTGGAGT TGGGAAGCTA GACACTGCCC CCCTACATAA GAATAAGTCT
23
24 GGTGGCCCCA AACCATACCT GGAAACTAGG CAAGGAGCAA AGCCAGCAGA
25
26 TCCTACGGCC TGTGGGCCAG GGCCAG-AGC CTTCAGGGAC CTTGACTCC
27
28 CCGGGCTGTG TGCATTTTCTG ACGGGCTGTG CTGAACACTG CAGCTTGAAT
29
30 GAGAATATCA CTGTCCCGA CACCAGAGTT AATTTCTATG CCTGGAAGAG
31
32 GATGGAGGTG AGTTCCTTTT TTTTTTTTTT TCCTTTCTTT TGGAGAATCT
33
34 CATTTGCGAG CCTGATTTTG GATGAAAGGG AGAATGATCG GGGGAAAGGT
35
36 AAAATGGAGC AGCAGAGATG AGGCTGCCTG GGCGCAGAGG CTCACGTCTA
37
38 TAATCCCAGG CTGAGATGGC CGAGATGGGA GAATTGCTTG AGCCCTGGAG
39

DO NOT USE <400> line

50
100
↓

Per 1.822
of sequence
Rules, insert
the cumulative
base total at
end of each
line.

DO NOT use
upper-case
letters for
nucleic acids;
under new
sequence Rules,
use lower-case
letters for bases.

PAGE: 2

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042A

DATE: 10/28/1999

TIME: 14:00:56

Input Set: I029042A.RAW

E--> 40 GTTCAGACCA ACCTAGGCAG CATAGTGAGA TCCCCCATCT CTACAAACAT
W--> 41
E--> 42 TTAAAAAAT TAGTCAGGTG AAGTGGTGCA TGGTGGTAGT CCCAGATATT
W--> 43
E--> 44 TGGAAGGCTG AGGCGGGAGG ATCGCTTGAG CCCAGGAATT TGAGGCTGCA
W--> 45
E--> 46 GTGAGCTGTG ATCACACCAC TGCACTCCAG CCTCAGTGAC AGAGTGAGGC
W--> 47
E--> 48 CCTGTCTCAA AAAAGAAAAG AAAAAAGAAA AATAATGAGG GCTGTATGGA
W--> 49
E--> 50 ATACATTCAT TATTCATTCA CTCACCTACT CACTCATTCA TTCATTATT
W--> 51
E--> 52 CATTCAACAA GTCTTATTGC ATACCTTCTG TTTGCTCAGC TTGGTGCTTG
W--> 53
E--> 54 GGGCTGCTGA GGGGCAGGAG GGAGAGGGTG ACATGGGTCA GCTGACTCCC
W--> 55
E--> 56 AGAGTCCACT CCCTGTAGGT CGGGCAGCAG GCCGTAGAAG TCTGGCAGGG
W--> 57
E--> 58 CCTGGCCCTG CTGTCGGAAG CTGTCCTGCG GGGCCAGGCC CTGTTGGTCA
W--> 59
E--> 60 ACTCTTCCCA GCCGTGGGAG CCCCTGCAGC TGCATGTGGA TAAAGCCGTC
W--> 61
E--> 62 AGTGGCCTTC GCAGCCTCAC CACTCTGCTT CGGGCTCTGG GAGCCCAGGT
W--> 63
E--> 64 GAGTAGGAGC GGACACTTCT GCTTGCCCTT TCTGTAAGAA GGGGAGAAGG
W--> 65
E--> 66 GTCTTGCTAA GGAGTACAGG AACTGTCCGT ATTCCTTCCC TTTCTGTGGC
W--> 67
E--> 68 ACTGCAGCGA CCTCCTGTTT TCTCCTTGGC AGAAGGAAGC CATCTCCCCT
W--> 69
E--> 70 CCAGATGCGG CCTCAGCTGC TCCACTCCGA ACAATCACTG CTGACACTTT
W--> 71
E--> 72 CCGCAAATC TTCCGAGTCT ACTCCAATTT CCTCCGGGGA AAGCTGAAGC
W--> 73
E--> 74 TGTACACAGG GGAGGCCTGC AGGACAGGGG ACAGATGA
W--> 75

*Insert
Cumulative
base totals*

76 <210> 2
77 <211> 1582
78 <212> DNA

79 <213> erythropoietin

same error

E--> 80 (400) ATGGGGGTGC ACGAATGTCC TGCCTGGCTG TGGCTTCTCC TGTCCCTGCT
E--> 81 GTGCTCCCT CTGGGCTCC CAGTCCTGGG CGCCCCACCA CGCCTCATCT
W--> 82
E--> 83 GTGACAGCCG AGTCCTGGAG AGGTACCTCT GGAGGCCAAG GAGGCCGAG
W--> 84
E--> 85 AATATCACGG TGAGACCCCT TCCCAGCAC ATTCCACAGA ACTCACGCTC
W--> 86
E--> 87 AGGGCTTCAG GG-AACTCCT CCCAG-ATCC AGGAACCTGG CACTTGTTT
W--> 88

PAGE: 3

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042ADATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

E--> 89 GGGGTGGAGT TGGGAAGCTA GACACTGCCC CCCTACATAA GAATAAGTCT
W--> 90 GGTGGCCCCA AACCATACCT GGAAACTAGG CAAGGAGCAA AGCCAGCAGA
E--> 91
W--> 92 TCCTACGCC TGTGACCAG GGCCAGAGC CTTCAGGGAC CCTTGACTCC
E--> 93
W--> 94 CCGGGCTGTG TGCATTTCAG ACGGGCTGTG CTGAACACTG CAGCTTGAAT
E--> 95
W--> 96 GAGAATATCA CTGTCCCAGA CACCAAAGTT AATTTCTATG CCTGGAAGAG
E--> 97
W--> 98 GATGGAGGTG AGTTCCTTTT TTTTTTTTTT TCCTTTCTTT TGGAGAATCT
E--> 99
W--> 100
E--> 101 CATTTGCGAG CCTGATTTTG GATGAAAGGG AGAATGATCG AGGGAAAGGT
W--> 102
E--> 103 AAAATGGAGC AGCAGAGATG AGGCTGCCTG GGCGCAGAGG CTCACGTCTA
W--> 104
E--> 105 TAATCCCAGG CTGAGATGGC CGAGATGGGA GAATTGCTTG AGCCCTGGAG
W--> 106
E--> 107 GTTCAGACCA ACCTAGGCAG CATAGTGAGA TCCCCCATCT CTACAAACAT
W--> 108
E--> 109 TTAAAAAAT TAGTCAGGTG AAGTGGTGCA TGGTGGTAGT CCCAGATATT
W--> 110
E--> 111 TGGAAGGCTG AGGCGGGAGG ATCGCTTGAG CCCAGGAATT TGAGGCTGCA
W--> 112
E--> 113 GTGAGCTGTG ATCACACCAC TGCACTCCAG CCTCAGTGAC AGAGTGAGGC
W--> 114
E--> 115 CCTGTCTCAA AAAAGAAAAG AAAAAAGAAA AATAATGAGG GCTGTATGGA
W--> 116
E--> 117 ATACGTTTCA TATTCATTCA CTCCTCACT CACTCATTCA TTCATTCA
W--> 118
E--> 119 CATTCAACAT GTCTTATTGC ATACCTTCTG TTTGCTCAGC TTGGTGCTTG
W--> 120
E--> 121 AGAGTCCACT CCCTGTAGGT CGGGCAGCAG GCCGTAGAAG TCTGGCAGGG
W--> 122
E--> 123 CCTGGCCCTG CTGTCGGAAG CTGTCCTGCG GGGCCAGGCC CTGTTGGTCA
W--> 124
E--> 125 ACTCTTCCCA GCCGTGGGAG CCCCTGCAGC TGCATGTGGA TAAAGCCGTC
W--> 126
E--> 127 AGTGGCCTTC GCAGCCTCAC CACTCTGCTT CGGGCTCTGG GAGCCCAGGT
W--> 128
E--> 129 GAGTAGGAGC GGACACTTCT GCTTGCCCTT TCTGTAAGAA GGGGAGAAGG
W--> 130
E--> 131 GTCTTGCTAA GGAGTACAGG AACTGTCCGT ATTCCTTCCC TTTCTGTGGC
W--> 132
E--> 133 ACTGCAGCGA CCTCCTGTTT TCTCCTTGGC AGAAGGAAGC CATCTCCCCT
W--> 134
E--> 135 CCAGATGCGG CCTCAGCTGC TCCACTCCGA ACAATCACTG CTGACACTTT
W--> 136
E--> 137 CCGCAAATC TTCCGAGTCT ACTCCAATT CCTCCGGGA AAGCTGAAGC
W--> 138

PAGE: 4

 RAW SEQUENCE LISTING
 PATENT APPLICATION US/09/029,042A

 DATE: 10/28/1999
 TIME: 14:00:56

Input Set: I029042A.RAW

E--> 139 TGTACACAGG GGAGGCCTGC AGGACAGGGG ACAGATGA
 W--> 140

141 <210> 3
 142 <211> 1585
 143 <212> DNA
 144 <213> erythropoietin *73*
 E--> 145 <400> ATGGGGGTGC ACGAATGTCC TGCCTGGCTG TGGCTTCTCC TGTCCCTGCT
 E--> 146 GTCGCTCCCT CTGGGCCTCC CAGTCCTGGG CGCCCCACCA CGCCTCATCT
 W--> 147 GTGACAGCCG AGTCCTGGAG AGGTACCTCT TGGAGGCCAA GGAGGCCGAG
 E--> 148 AATATCACGG TGAGACCCCT TCCCCAGCAC ATTCCACAGA ACTCACGCTC
 W--> 149 AGGGCTTCAG GG-AACTCCT CCCAG-ATCC AGGAACCTGG CACTTGGTTT
 E--> 152 GGGGTGGAGT TGGGAAGCTA GACACTGCCC CCCTACATAA GAATAAGTCT
 W--> 153 GGTGGCCCCA AACCATACCT GGAAACTAGG CAAGGAGCAA AGCCAGCAGA
 E--> 156 TCCTACGGCC TGTGGGCCAG GGCCAA-AAC CTTCAGGGAC CTTGACTCC
 W--> 157 CCGGGCTGTT TGCATTTTCTAG ACGGGCTGTG CTGAACACTG CAGCTTGAAT
 E--> 158 GAAAATATCA CTGTCCCAGA CACCAAAGTT AATTTCTATG CCTGGAAGAG
 W--> 161 GATGGAGGTG AGTTCCTTTT TTTTTTTTTT TCCTTTCTTT TGGAGAATCT
 E--> 162 CATTGCGAG CCTGATTTTG GATGAAAGGG AGAATGATCG AGGGAAAGGT
 W--> 163 AAAATGGAGC AGCAGAGATG AGGCTGCCTG GGCGCAGAGG CTCACGTCTA
 E--> 164 TAATCCCAGG CTGAGATGGC CGAAATGGGA GAATTGCTTG AGCCCTGGAG
 W--> 165 GTTCAGACCA ACCTAGGCAG CATAGTGAGA TCCCCCATCT CTACAAACAT
 E--> 166 TTAAAAAAT TAGTCAGGTG AAGTGGTGCA TGGTGGTAGT CCCAGATATT
 W--> 167 TGGATGGCTG AGGCGGGAGG ATCGCTTGAG CCCAGGAATT TGAGGCTGCA
 E--> 168 GTGAGCTGTG ATCACACCAC TGCACTCCAG CCTCAGTGAC AGAATGAGGC
 W--> 169 CCTGTCTCAA AAAAGAAAAG AAAAAAGAAA AATAATGAGG GCTGTATGGA
 E--> 170 ATACATTCAT TATTCATTCA CTCCTCACT CACTCATCCA TTCATTCAAT
 W--> 171 CATTCAACAA GTCTTATTGC ATACCTTCTG TTTGCTCAGC TTGGTGCTCG
 E--> 172 GGGCTGCTGA GGGGCAGGAG GGAGAGGGTG ACATGGGTCA GCTGACTCCC
 W--> 173
 E--> 174
 W--> 175
 E--> 176
 W--> 177
 E--> 178
 W--> 179
 E--> 180
 W--> 181
 E--> 182
 W--> 183
 E--> 184
 W--> 185
 E--> 186
 W--> 187

PAGE: 5

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042A

DATE: 10/28/1999

TIME: 14:00:56

Input Set: I029042A.RAW

E--> 188 AGAGTCCACT CCCTGTAGGT CGGGCAACAG GCCGTAGAAG TCTGGCAGGG
W--> 189 CCTGGCCCTG CTGTCGGAAG CTGTCCTGCG GGGCCAGGCC CTGTTGGTCA
E--> 190 ACTTTTCCCA GCCGTGGGAG CCCCTGCAGC TGCATGTGGA TAAAGCCGTC
W--> 191 AGTGGCCTTC GCAGCCTCAC CACTCTGCTT CGGGCTCTGG GAGCCCAGGT
E--> 192 GAGTAGGAGC GGACACTTCT GCTTGCCCTT TCTGTAAGAA GGGGAGAAGG
W--> 193 GTCTTGCTAA GGAGTACAGG AACTGTCCGT ATTCTTCCC TTTCTGTGGC
E--> 194 ACTGCAGCGA CCTCCTGTTT TCTCCTTGGC AGAAGGAAGC CATCTCCCCT
W--> 195 CCAGATGCGG CCTCAGCTGC TCCACTCCGA ACAATCACTG CTGACACTTT
E--> 196 CCGCAAATC TTCCGAGTCT ACTCCAATT CCTCCGGGGA AAGCTGAAGC
W--> 197 TGTACACAGG GGAGGCCTGC AGGACAGGGG ACAGATGA
E--> 200
W--> 201
E--> 202
W--> 203
E--> 204
W--> 205
E--> 206
W--> 207

208 <210> 4
209 <211> 1585
210 <212> DNA

211 <213> erythropoietin -> 4

E--> 212 <400> ATGGGGGTGC ACGAATGTCC TGCCTGGCTG TGGCTTCTCC TGTCCCTGCT
E--> 213 GTCGCTCCCT CTGGGCCTCC CAGTCCTGGG CGCCCCACCA CGCCTCATCT
W--> 214 GTGACAGCCG AGTCCTGGAG AGGTACCTCT TGGAGGCCAA GGAGGCCGAG
E--> 215 AATATCACGG TGAGACCCCT TCCCCAGCAC ATTCCACAGA ACTCACGCTC
W--> 216 AGGGCTTCAG GGAACTCCT CCCAGATCC AGGAACCTGG CACTTGGTTT
E--> 217 GGGGTGGAGT TGGGAAGCTA GACACTGCCC CCCTACATAA GAATAAGTCT
W--> 218 GGTGGCCCCA AACCATACCT GGAAACTAGG CAAGGAGCAA AGCCAGCAGA
E--> 219 TCCTACGGCC TGTGGGCCAG GGCCAGGAGC CTTCAGGGAC CTTGACTCC
W--> 220 CCGGGCTGTG TGCATTTTCA AAGGGCTGTG CTGAACACTG CAGCTTGAAT
E--> 221 GAGAATATCA CTGTCCAGA CACCAAAGTT AATTTCTATG CCTGGAAGAG
W--> 222 GATGGAGGTG AGTTCCTTTT TTTTTTTTTT TCCTTTCTTT TGGAGAATCT
E--> 223 CATTTGCGAG CCTGATTTTG GATGAAAGGG AGAGTGATCG AGGGAAAGGT
W--> 224 AAAATGGAGC AGCAGAGATG AGGCTGCCTG GGCGCAGAGG CTCACGTCTA
E--> 225
W--> 226
E--> 227
W--> 228
E--> 229
W--> 230
E--> 231
W--> 232
E--> 233
W--> 234
E--> 235
W--> 236

PAGE: 6

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042A

DATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

```

E--> 237      TAATCCCAGG CTGAGATGGC CGAGATGGGA GAATTGCTTG AGCCCTGGAG
W--> 238      GTTCAGACCA ACCTAGGCAG CATAGTGAGA TCCCCCATCT CTACAAACAT
E--> 239      TTAAAAAAT TAGTCAGGTG AAGTGGTGCA TGGTGGTAGT CCCAGATATT
W--> 240      TGGAAGGCTG AGGCGGGAGG ATCGCTTGAG CCCAGGAATT TGAGGCTGCC
E--> 241      GTGAGCTGTG ATCACACCAC TGCACCTCCAG CCTCAGTGAC AGAGTGAGGC
W--> 242      CCTGTCTCAA AAAAGAAAAG AAAAAAGAAA AATAATGAGG GCTGTATGGA
E--> 243      ATACATTCAT TATTCATTCA CTCACCTACT CACTCATTCA TTCATTATT
W--> 244      CATTCAACAA GTCTTATTGC ATACCTTCTG TTTGCTCAGC TTGGTGCTTG
E--> 245      GGGCTGCTGA GGGGCAGGAG GGTGAGGGTG ACATGGGTCA GCTGACTCCC
W--> 246      AGAGTCCACT CCCTGTTGGT CGGGCAGCAG GCCGTAGAAG TCTGGCAGGG
E--> 247      CCTGGCCCTG CTGTCGGAAG CTGTCTTGCG GGGCCAGGCC CTGTTGGTCA
W--> 248      ACTCTTCCCA GCCGTGGGAG CCCCTGCAGC TGCATGTGGA TAAAGCCGTC
E--> 249      AGTGGCCTTC GCAGCCTCAC CACTCTGCTT CGGGCTCTGG GAGCCCAGGT
W--> 250      GAGTAGGAGC GGACACTTCT GCTTGCCCTT TCTGTAAGAA GGGGAGAAGG
E--> 251      GTCTTGCTAA GGAGTACAGG AACTGTCCGT ATTCCTTCCC TTTCTGTGGC
W--> 252      ACTGCAGCGA CCTCCTGTTT TCTCCTTGGC AGAAGGAAGC CATCTCCCCT
E--> 253      CCAGATGCGG CCTCAGCTGC TCCACTCCGA ACAATCACTG CTGACACTTT
W--> 254      CCGCAAATCT TTCCGAGTCT ACTCCAATTT CCTCCGGGGA AAGCTGAAGC
E--> 255      TGTACACAGG GGAGGCCTGC AGGACAGGGG ACAGATGA
W--> 256
E--> 257
W--> 258
E--> 259
W--> 260
E--> 261
W--> 262
E--> 263
W--> 264
E--> 265
W--> 266
E--> 267
W--> 268
E--> 269
W--> 270
E--> 271
W--> 272
E--> 273
W--> 274

```

275 <210> 5
276 <211> 1583
277 <212> DNA

278 <213> erythropoietin) 5

E--> 279 <400> ATGGGGGTGC ACGAATGTCC TGCCTGGCTG TGGCTTCTCC TGTCCCTGCT
E--> 280 GTCGCTCCCT CTGGGCCTCC CAGTCCTGGG CGCCCCACCA CGCCTCATCT
W--> 281
E--> 282 GTGACAGACG AGTCCTGGAG AGGTACCTCT TGGAGGCCAA GGAGGCCGAG
W--> 283
E--> 284 AATATCACGG TGAGACCCCT TCCCAGCAC ATTCCACAGA ACTCACGCTC
W--> 285

PAGE: 7

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042ADATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

E--> 286 AGGGCTTCAG GG-AACTCCT CCCAG-ATCC AGGAACCTGG CACTTGGTTT
W--> 287 GGGGTGGAGT TGGGAAGCTA GACACTGCCC CCCTACATAA GAATAAGTCT
E--> 288 GGTGGCCCCA AACCATACCT GGAAACTAGG CAAGGAGCAA AGCCAGCAGA
W--> 289 TCCTACGGCC TGTGGCCCAG GGGCA-GAGC CTTGAGGGAC CCTTGACTCC
E--> 292 CCGGGCTGTG TGCATTTCAG ACGGGCTGTG CTGAACACTG CAGCTTGAAT
W--> 293 GAGAATATCA CTGTCCCAGA CACCAAAGTT AATTTCTATG CCTGGAAGAG
E--> 296 GATGGAGGTG AGTTCCTTTT TTTTTTTT-- TCCTTTCTTT TGGAGAATCT
W--> 297 CATTTGCGAG CCTGATTTTG GATGAAAGGG AGAATGATCG AGGGAAAGGT
E--> 300 AAAATGGAGC AGCAGAGATG AGGCTGCCTG GGCGCAGAGG CTCACGTCTA
W--> 301 TAATCCCAGG CTGAGACGGC CGAGATGGGA GAATTGCTTG AGCCCTGGAG
E--> 302 GTTCAGACCA ACCTAGGCAG CATAGTGAGA TCCCCATCT CTACAAACAT
W--> 303 TTAAAAAAT TAGTCAGGTG AAGTGGTGCA TGGTGGTAGT CCCAGATATT
E--> 306 TGAAGGCTG AGGCGGGAGG ATCGCTTGAG CCCAGGAATT TGGGGCTGCA
W--> 307 GTGAGCTGTG ATCACACCAC TGCAATCCAG CCTCAGTGAC AGAGTGAGGC
E--> 312 CCTGTCTCAA AAACGAAAAG AAAAAAGAAA AATAATGAGG GCTGTATGGA
W--> 313 ATACATTCAT TATTCATTCA CTCACTCACT CACTCATTCA TTCATTCAAT
E--> 316 CATTCAACAA GTCTTATTGC ATACCTTCTG TTTGCTCAGC TTGGTGCTTG
W--> 317 GGCCTTCTGA GGGGCAGGAG GGAGAGGGTG ACATGGGTCA GCTGACTCCC
E--> 320 AGAGTCCACT CCCTGTAGGT CGGGCAGCAG GCCGTAGAAG TCTGGCAGGG
W--> 321 CCTGGCCCTG CTGTCGGAAT CTGTCCTGCG GGGCCAGGCC CTGTTGGTCA
E--> 324 ACTCTTCCCA ACCGTGGGAG CCCCTGCAGC TGCATGTGGA TAAAGCCGTC
W--> 325 AGTGGCCTTC GCAGCCTCAC CACTCTGCTT CGGGCTCTGG GAGCCCAGTT
E--> 328 GAGTAGGAGG GGACACTTCT GCTTGCCCTT TGTGTAAGAA GGAGAGAAGG
W--> 329 GTCTTGCTAA GGAGTACAGG AACTGTCCGT ATTCCTTCCC TTTCTGTGGC
E--> 332 ACTGCAGCGA CCTCCTGTTT TCTCCTTGGC AGAAGGAAGC CATCTCCCCT
W--> 335

PAGE: 8

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042ADATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

E--> 336 CCAGATGCGG CCTCAGCTGC TCCACTCCGA ACAATCACTG CTGATACTTT
W--> 337 CCGCAAATCT TTCCGAGTCT ACTCCAATTT CCTCCGGGGA AAGCTGAAGC
E--> 338
W--> 339 TGTACACAGG GGAGGCCTGC AGGACAGGGG ACAGATGA
E--> 340
W--> 341

342 <210> 6
343 <211> 1586
344 <212> DNA
345 <213> erythropoietin
E--> 346 <400> ATGGGGGTGC ACGAATGTCC TGCCTGGCTG TGGCTTCTCC TGTCCCTGCT
E--> 347 GTCGCTCCCT CTGGGCCTCC CAGTCCTGGG CGCCCCACCA CGCCTCATCT
W--> 348
E--> 349 GTGACAGCCG AGTCCTGGAG AGGTACCTCT TGGAGGCCAA GGAGGCCGAG
W--> 350
E--> 351 AATATCACGG TGAGACCCCT TCCCCAGCAC ATTCCACAGA ACTCACGCTC
W--> 352
E--> 353 AGGGCTTCAG GGGAACTCCT CCCAGGATCC AGGAACCTGG CACTTGGTTT
W--> 354
E--> 355 GGGGTGGAGT TGGGAAGCTA GACACTGCCC CCCTACATAA GAATAAGTCT
W--> 356
E--> 357 GGTGGCCCCA AACCATACCT GGAACTAGG CAAGGAGCAA AGCCAGCAGA
W--> 358
E--> 359 TCCTACGGCC TGTGGCCAG GGCCA GAGC CTTCAGGGAC CTTGACTCC
W--> 360
E--> 361 CCGGGCTGTG TGCATTCCAG ACGGGCTGTG CTGAACACTG CAGCTTGAAT
W--> 362
E--> 363 GAGAATATCA CTGTCCCAGA CACCAAAGTT AATTTCTATG CCTGGAAGAG
W--> 364
E--> 365 GATGGAGGTG AGTTCCTTTT TTTTTTTTTT TCCTTTCTTT TGGAGAATCT
W--> 366
E--> 367 CATTTGCGAG CCTGATTTGG GATGAAAGGG AGAATGATCG AGGGAAAGGT
W--> 368
E--> 369 AAAATGGAGC AGCAGAGATG AGGCTGCCTG GCGCAGAGG CTCCAGTCTA
W--> 370
E--> 371 TAATCCCAGG CTGAGATGGC CGAGATGGGA GAATTGCTTG AGCCCTGGAG
W--> 372
E--> 373 GTTCAGACCA ACCTAGGCAG CCTAGTGAGA TCCCCATCT CTACAAACAT
W--> 374
E--> 375 TTAAAAAAT TAGTCAGGTG AAGTGGTGCA TGGTGGTAGT CCCAGATATT
W--> 376
E--> 377 TGGAAGGCTG AGGCGGGAGG ATCGCTTGAG CCCAGGAATT TGAGGCTGCA
W--> 378
E--> 379 GTGAGCTGTG ATCACACCAC TGCACTCCAG CCTCAGTGAC AGAGTGAGGC
W--> 380
E--> 381 CCTGTCTCAA AAAAGAAAAG AAAAAAGAAA AATTATGAGG GCTGTATGGA
W--> 382
E--> 383 ATACATTCAT TATTCATTCA CTCCTCACT CACTCATTCATT
W--> 384

PAGE: 9

RAW SEQUENCE LISTING PATENT APPLICATION US/09/029,042A

DATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

```

E--> 385      CATTCAACAA GTCTTATTGC ATACCTTCTG TTTGCTCAGC TTGGTGCTTG
W--> 386      GGGCTGCTGA GGGGCAGGAG GGAGAGGGTG ACATGGGITC ACTGACTCCC
E--> 387
W--> 388      AGAGTCCACT CCCTGTAGGT CGGGCAGCAG GCCGTAGAAG TCTGGCAGGG
E--> 389
W--> 390      CCTGGCCCTG CTGTCGGAAG CTGTCCTGCG GGGCCAGGCC CTGTTGGTCA
E--> 391
W--> 392      ACTCTTCCCA GCCGTGGGAG CCCCTGCAGC TGCATGTGGA TAAAGCCGTC
E--> 393
W--> 394      AGTGGCCTTC GCAGCCTCAC CACTCTGCTT CGGGCTCTGG GAGCCCAGGT
E--> 395
W--> 396      GAGTAGGAGC GGACACTTCT GCTTGCCCTT TCTGTAAGAA GGGGAGAAGG
E--> 397
W--> 398      GTCTTGCTAA GGAGTACAGG ATCTGTCCGT ATTCCTTCCC TTTCTGTGGC
E--> 399
W--> 400      ACTGCAGCGA CCACCTGTTT TCTCCTTGGC AGAAGGAAGC CATCTCCCCT
E--> 401
W--> 402      CCAGATGCGG CCTCAGCTGC TCCACTCCGA ACAATCACTG CTGACACTTT
E--> 403
W--> 404      CCGCAAATC TTCCGAGTCT ACTCCAATTT CCTCCGGGGA GAGCTGAAGC
E--> 405
W--> 406      TGTACACAGG GGAGGCCTGC AGGACAGGGG ACGGATGA
E--> 407
W--> 408

```

```

E--> 409      <210> 7
E--> 410      <211> 193
E--> 411      <212> PRT
E--> 412      <213> erythropoietin gene
E--> 413      <400> Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu
E--> 414      Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Arg Leu
E--> 415      Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
E--> 416
E--> 417      Ala Glu
E--> 418
E--> 419      Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu Asn Ile
E--> 420
E--> 421      Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu
E--> 422
E--> 423      Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser
E--> 424
E--> 425      Glu Ala
E--> 426
E--> 427      Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu
E--> 428
E--> 429      Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu
E--> 430
E--> 431      Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro
E--> 432
E--> 433

```

do not show amino acids next to
24007

per 1.822

of
sequence
number

the amino
acid
order

every 5
amino acids.

Do NOT use
TAB codes

between
amino acid nos.

Use space
characters.

PAGE: 10

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042A

DATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

434 Pro Asp
E--> 435 Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg
436
E--> 437 Lys Leu Phe Arg Val Val Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu
438
E--> 439 Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg
440
E--> 441

442 <210> 8
E--OK 443 <211> 193
444 <212> PRT
445 <213> erythropoietin gene
E--> 446 <400> Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
447 Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu
E--> 448 Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
449
E--> 450 Ala Glu
451
E--> 452 Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu Asn Ile
453
E--> 454 Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu
455
E--> 456 Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser
457
E--> 458 Glu Ala
459
E--> 460 Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu
461
E--> 462 Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu
463
E--> 464 Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro
465
E--> 466 Pro Asp
467
E--> 468 Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg
469
E--> 470 Lys Leu Phe Arg Val Val Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu
471
E--> 472 Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg
473
E--> 474

475 <210> 9
E--OK 476 <211> 193
477 <212> PRT
478 <213> erythropoietin gene
E--> 479 <400> Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
480 Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu
E--> 481

same error

number
the
amino
acids
under
every 5
amino
acids
Do NOT
use TAB
codes.

number
amino
acids

PAGE: 11

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042A

DATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

482 Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
E--> 483 Ala Glu
484
E--> 485 Asn Ile Thr Lys Gly Cys Ala Glu His Cys Ser Leu Asn Glu Asn Ile
486
E--> 487 Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu
488
E--> 489 Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser
490
E--> 491 Glu Ala
492
E--> 493 Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu
494
E--> 495 Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu
496
E--> 497 Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro
498
E--> 499 Pro Asp
500
E--> 501 Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg
502
E--> 503 Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu
504
E--> 505 Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg
506

507 <210> 10
E--OK 508 <211> 193
509 <212> PRT
510 <213> erythropoietin gene -> 10
E--> 511 <400> Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
512 Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu
E--> 513 Ile Cys Asp Arg Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
514
E--> 515 Ala Glu
516
E--> 517 Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu Asn Ile
518
E--> 519 Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu
520
E--> 521 Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser
522
E--> 523 Glu Ser
524
E--> 525 Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu
526
E--> 527 Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu
528
E--> 529 Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro
530

PAGE: 12

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/029,042A

DATE: 10/28/1999
TIME: 14:00:56

Input Set: I029042A.RAW

E--> 531
532 Pro Asp
E--> 533
534 Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg
E--> 535
536 Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu
E--> 537
538 Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg
E--> 539

540 <210> 11
E--> OK 541 <211> 193
542 <212> PRT
543 <213> erythropoietin gene > //
E--> 544 <400> Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
545 Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu
E--> 546
547 Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
E--> 548
549 Ala Glu
E--> 550
551 Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu Asn Ile
E--> 552
553 Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu
E--> 554
555 Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser
E--> 556
557 Glu Ala
E--> 558
559 Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu
E--> 560
561 Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu
E--> 562
563 Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro
E--> 564
565 Pro Asp
E--> 566
567 Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg
E--> 568
569 Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Glu Leu Lys Leu
E--> 570
571 Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Gly
E--> 572

1
Delete at end of file

↓ FYI

Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220> to
<223> fields of each sequence which presents at least one n or Xaa.

Appendix A To Subpart G to Part 1—Sample Sequence Listing

<110> Smith, John

Smith, Jane

<120> Example of a Sequence Listing

<130> 01-00001

<140> US 08/999,999

<141> 1998-02-28

<150> EP 91000000

<151> 1997-12-31

Please consult.

<160> 2

<170> PatentIn ver. 2.0

<210> 1

<211> 403

<212> DNA

<213> Paramecium aurelia

<220>

<221> CDS

<222> 341..394

<300>

<301> Doe, Richard

<302> Isolation and Characterization of a Gene Encoding a

Protease from Paramecium sp.

<303> Journal of Fictional Genes

<304> 1

<305> 4

<306> 1 - 7

<307> 1988-06-20

<400> 1

ctactctact ctactctcat ctactatctt ctttggatct ctgagtctgc ctgagtggta 60

ctcttgagtc ctggagatct ctctctcac atgtgatcgt cgagactgac cgatagatcg 120

ctgactgact ctgagatagt cgagcccgta cgagaccgt cgagggtgac agagagtggg 180

cgcggtgcgcg cagagcgccg cgccgggtgcg cgcgcgagtg cgcggtgggc cgcgcgaggg 240

ctttcgcggc agcggcggcg ctttcggcg cgcgcccgtc cgcccctaga cctgagaggt 300

cttctcttcc ctctcttca ctagagaggt ctatatatac atg gtt tca atg ttc 355

Met Val Ser Met Phe

agc ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgtttgctc 403

Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val

10

15

<210> 2

<211> 18

<212> PRT

<213> Paramecium aurelia

<400> 2

Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu

1

5

10

15

Phe Val

ed: May 22, 1998.

A. Lehman,

ant Secretary of Commerce and
missioner of Patents and Trademarks.

oc. 98-14194 Filed 5-29-98; 8:45 am]

1 CODE 3510-16-C

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO: #:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	0
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	0
<302>	Title		0
<303>	Journal		0
<304>	Volume		0
<305>	Issue		0
<306>	Pages		0
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	0
<308>	Database Accession Number	Accession number assigned by database including database name	0
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	0
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	0

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	O
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.824 is revised to read as follows:

1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.821(e) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;